AI-FIRST RESEARCH AND BUILDS
For one deal you would hire a financial statement analyst, a market researcher, someone to check the team's track record and an exit modeler. We built each of those specialists as an AI agent on the newest models, and our analysts direct them on your deal. Your first screen is free, within 24 hours.
Overall B-
| Category | Grade | Rationale |
|---|---|---|
| Team | B | No one on the team is named on an FDA-cleared 510(k). |
| Metrics | C | The USD 240,000 ARR is a run-rate built from one USD 18,000 placement. |
| Deal terms | C+ | The 2025 SAFE cap sits 36% below a round no lead has priced. |
Specimen and illustration. Thornlark Diagnostics is a fictional company.
THE FLOOR
Each specialist desk is one AI agent, built to do that one job. Our analysts direct the agents from the middle of the floor, and a principal reads and signs every paper before it leaves.
See what each agent does Lensential VentureLensential PELensential Consult
THE SCHEDULE
An illustrative full diligence on a startup in Lensential Venture. Sixteen agents work in order, and the ones that verify the company run at the same time. Our analysts direct them and read what they find.
BUSINESS DAY
12345678910Our analysts, all ten days
SCREEN
Deal screen, day 1
PROFILE
Company profile, days 1 to 2
VERIFY
Document provenance, day 2
Registry chronology, days 2 to 3
Data room forensics, days 2 to 5
Founder verification, days 2 to 4
Cap table verification, days 2 to 4
Competitive position, days 2 to 5
Traction verification, days 3 to 6
Product verification, days 3 to 5
Build assessment, days 3 to 6
LAND
Exit model, days 6 to 8
Diligence report, days 6 to 9
Founder questions, days 7 to 8
DECIDE
Committee decision paper, days 9 to 10
SHARE
Investment memo, day 10
Our analysts, all ten days
SCREEN
PROFILE
VERIFY
LAND
DECIDE
SHARE
A principal reads and signs
For a buyout in Lensential PE, a check of the numbers comes within five business days of access to the company's documents, and the full report within fifteen. After the free first screen, every paper has a fixed fee, agreed before work begins.
Illustrative schedule. The days count from access to the company's documents.
RESEARCH FOR INVESTORS
Diligence, exit math and the committee paper, without another hire.
Screen the whole cycle, and brief members on the few that make it.
Every deal your office sees, from a seed round to a buyout, checked to one standard.
Test the seller's numbers before you price the deal.
STUDIES FOR ONE DECISION
BUILDS FOR FINANCE TEAMS
The close, the consolidation and the lender pack across every company you bought.
The monthly pack built once, and the strategy work it feeds.
Automation built inside your firm, and checked research on single deals.
RESEARCH FOR STARTUP PROGRAMS
START WITH YOUR QUESTION
Each question opens the report or the build that answers it.
BUYOUT FUNDS ASK
BOARDS AND INVESTORS ASK
FOUNDERS ASK
FINANCE TEAMS ASK
TWO WAYS TO WORK WITH US
ORDER REPORTS
Send a name, a deck, a data room or a whole cycle of deal flow. Our analysts run the agents, a principal reads and signs the finished report, and we walk your partners or your committee through it. There is no software to learn and nobody to hire.
BUILD WITH US
An engineer from our bench builds the system inside your firm, on the same parts that run our own back office. Then we run it for you each month, run it with your team, or hand it over.
Your first screen is free: send the last deal you passed on, or the last one you funded.
Every build starts with a paid discovery of one to two weeks, scoped and priced in advance.
BUILT FOR OURSELVES FIRST
Before we built for anyone else, we built for our own work. Every client report runs on these systems, and every client build starts from these parts: the report renderer, the evidence standard and the stage method.
OUR STATEMENT Lensential Venture has produced hundreds of papers since mid-2026. Five investor groups are trialing it, and the principals use it on their own deals. How to check us
Route: Full diligence
The engagement file is updated after every agent. Later work resumes from it.
Route: Full diligence
The engagement file is updated after every agent. Later work resumes from it.
HOW AN ORDER WORKS
Write to us the way you would write to an associate. The report comes back as finished files: PDF for evidence, live Excel for the math, Word for anything you will edit. An analyst presents it to your partners, and if a finding changes later, you get the correction with the earlier reading kept. Every delivery time includes a principal's reading and signature, and starts when the input arrives.
You
Thornlark Diagnostics
Thornlark is raising USD 2.5 million at USD 14 million post. Deck, cap table and data room link attached. Is it worth our time, and can we make money at this price?
Lensential
Attached is the Screen, with an exit read. The Exit Brief and the live exit workbook follow within five business days. Overall B-. At this price, returning 3x after the Series B needs a USD 73.5 million exit, about 19% of the highest price buyers paid for a comparable company. The return depends on regulatory clearance. The full Screen ends with three questions for the founder and three documents to request. We can take your partners through it on a call.
Lensential
One correction. The 2025 SAFE is a post-money instrument, so it converts to 6.85% of the post-close table, not the 5.4% in the Screen. The register is attached, with the earlier reading kept.
Specimen exchange. Thornlark Diagnostics is a fictional company. The same exchange works in your own messaging channel, such as Slack.
ONE STANDARD
Four signed evaluation agreements
Executed copies in the data room, four distinct counterparties. None carries a purchase commitment.
USD 4.1 billion addressable market
The site count and the payment amount are both verified. The payment covers the whole test panel; the product measures one analyte.
18-minute sample-to-result turnaround
Company bench measurement. No third-party run, no published protocol, no independent replication.
USD 240,000 ARR
The underlying invoice is USD 18,000 to place the product once, so it is not recurring revenue.
Classifier trained on 1,240 samples
Company-stated, consistent across the deck and the technical memo. No data-use agreement was provided.
Regulatory clearance history for the team
No team member is named on an FDA-cleared 510(k). Searched the FDA premarket database under every name variant.
Specimen pages. Thornlark Diagnostics is a fictional company.
Established against an authoritative or independent source, and reproducible.
Established in substance, with a material qualification.
Asserted, and neither confirmed nor contradicted. Not a false claim.
Contradicted by an authoritative source or by the company's own materials.
A company figure carried for analysis, with no independent support.
Not disclosed and not found. We name where we looked.
We do not recommend for or against an investment. We give you the evidence and the math, and the decision stays yours.
Read the six rulesHOW WE DIFFER
Platforms such as Dealum and Decile Hub run pipelines, members, portfolios and funds, and both now use AI. We do not replace them. We deliver checked research on the companies in them.
We do not sell portfolio monitoring software. Your platform already does that, and we work from the data you keep there.
Dealum and Decile Hub are trademarks of their owners. They are not affiliated with Lensential.
See the comparison, with sourcesYour first screen is free, within 24 hours.